Sorafenib With or Without Paclitaxel and Carboplatin in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Inclusion Criteria

• •Diagnosis of ovarian epithelial, primary peritoneal, or fallopian tube cancer
• •Recurrent disease
• •Must have received a prior platinum-based regimen
• •Platinum-sensitive (treatment-free interval \> 6 months)
• •No more than 2 prior chemotherapy regimens
• •Measurable disease
• •At least 1 unidimensionally measurable lesion \>= 20 mm by conventional techniques OR \>= 10 mm by spiral CT scan
• •Not in a prior irradiation field
• •No known brain metastases
• •Performance status:
• •* ECOG 0-2 OR
• •* Karnofsky 80-100%
• •Life expectancy:
• •* More than 12 weeks
• •Hematopoietic:
• •* Absolute neutrophil count \>= 1,500/mm3
• •* Platelet count \>= 100,000/mm3
• •* Hemoglobin \>= 9 g/dL
• •* No bleeding diathesis
• •Hepatic:
• •* Bilirubin \< 1.5 times upper limit of normal (ULN)
• •* AST or ALT =\< 2 times ULN
• •No history of allergic reaction attributed to compounds of similar chemical or biological composition to sorafenib or other agents used in the study
• •Patients who have had a reaction to a taxane or a platinum and have not yet been rechallenged may undergo a desensitization regimen on study
• •No hypersensitivity to paclitaxel or drugs using the vehicle Cremophor El:
• •Prior hypersensitivity reaction to paclitaxel allowed provided rechallenged successfully
• •Renal:
• •* Creatinine \< 2 mg/dL
• •Cardiovascular:
• •* Abnormal cardiac conduction (e.g., bundle branch block or heart block) allowed if stable for the past 6 months
• •* No symptomatic congestive heart failure
• •* No uncontrolled hypertension
• •* No cardiac arrhythmia
• •* No unstable angina pectoris;
• •* No myocardial infarction within the past 6 months
• •Negative pregnancy test
• •Fertile patients must use effective contraception
• •Adequate intestinal function
• •No concurrent requirements for IV hydration or nutritional support
• •No active or ongoing infection
• •No psychiatric illness or social situation that would preclude study compliance
• •No other concurrent uncontrolled illness
• •No other invasive malignancy with the past 5 years except nonmelanoma skin cancer
• •More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered
• •More than 3 weeks since prior hormonal therapy
• •More than 4 weeks since prior radiotherapy and recovered
• •No prior sorafenib
• •No prior anticancer therapy that contraindicates study therapy
• •No concurrent cytochrome P450 enzyme-inducing antiepileptic drugs (phenytoin, carbamazepine, or phenobarbital), rifampin, or Hypericum perforatum (St. John's wort)
• •No concurrent combination antiretroviral therapy for HIV-positive patients
• •No concurrent therapeutic anticoagulation therapy
• •Concurrent prophylactic low-dose warfarin allowed for maintenance of venous or arterial access devices
• •No other concurrent anticancer therapies
• •No other concurrent investigational agents
• •Not pregnant or nursing